The TLR agonists used in vaccine formulations come in various forms, ranging from lipopeptides to single-stranded DNA and RNA.

This article summarized the latest R&D progress of Nepafenac, the Mechanism of Action for Nepafenac, and the drug target R&D trends for Nepafenac.

MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA).

This article summarized the latest R&D progress of Nemolizumab, the Mechanism of Action for Nemolizumab, and the drug target R&D trends for Nemolizumab.

Challenging the pathogenicity of bacteria through Bacteriophage therapy could lead the way to improved antibiotic strategies.

This article summarized the latest R&D progress of Mycophenolate Sodium, the mechanism of action for Mycophenolate Sodium, and the drug target R&D trends for Mycophenolate Sodium.

TLRs are innate immune receptors that are responsible, directly or indirectly, for detecting pathogen-associated molecular patterns (PAMPs) and responding to them through the activation of innate and adaptive immune pathways.

Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.

This article summarized the latest R&D progress of Naftifine Hydrochloride, the Mechanism of Action for Naftifine Hydrochloride, and the drug target R&D trends for Naftifine Hydrochloride.

TTerns Pharmaceuticals reported the initial participant administration in Phase 1 Clinical Testing of TERN-601 Oral GLP-1 Receptor Agonist, a potential treatment for obesity.

Mesenchymal stem cells (MSCs) have broad therapeutic potential for treating inflammation and degenerative diseases.

This article summarized the latest R&D progress of Naloxegol Oxalate, the Mechanism of Action for Naloxegol Oxalate, and the drug target R&D trends for Naloxegol Oxalate.